First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed...

Boston Scientific Europe today announced the launch of the HeartLogic™ Heart Failure Diagnostic in Europe. With this launch, the first and only diagnostic tool that enables proactive heart...

Today, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization...

Introducing SmartCRT™ technology, providing MultiSite Pacing with up to 13.3 years battery life.i Boston Scientific Europe today announced the launch of the RESONATE™ cardiac resynchronisation...

Boston Scientific (NYSE: BSX) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling...

Boston Scientific welcomes the updated ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death announced during ESC Congress 2015, the...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...

MILAN, Italy, June 23, 2014 – Attendees of EHRA EUROPACE-CARDIOSTIM 2015, a global medical conference held recently in Milan, Italy, have selected the EMBLEM™ S-ICD System as the most...

Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for...

SAVE THE DATE: June 23, 2015. Milan, Italy. Enterprise Hotel Corso Sempione, 91-93 20149 Milan, Italy We would like to invite you to our press event on June 23, 2015 dedicated to an innovative,...